Evidence-Based Summary
LL-37 and GHK-Cu represent the two essential phases of infected wound recovery: microbial clearance followed by structural tissue reconstruction. LL-37 is the sole human cathelicidin antimicrobial peptide, a 37-amino-acid amphipathic alpha-helical peptide cleaved from hCAP18 by neutrophils and epithelial cells upon injury. Acting in the earliest acute phase of wounding, LL-37 binds negatively charged bacterial membranes, forming toroidal pores that lyse invading bacteria (including Staphylococcus aureus and Pseudomonas aeruginosa) and neutralizing bacterial lipopolysaccharide (LPS) to prevent sepsis. In contrast, GHK-Cu is an endogenous copper-binding tripeptide (Gly-His-Lys:Cu2+) found in human plasma, saliva, and urine that orchestrates the subsequent proliferative and remodeling phases. Rather than lysing cell membranes, GHK-Cu delivers trace copper to activate lysyl oxidase, stimulates dermal fibroblasts to synthesize collagen types I and III, upregulates anti-fibrotic decorin, and balances matrix metalloproteinases (MMPs) to replace disorganized provisional fibrin with tensile, scar-resistant connective tissue. In chronic infected wounds, healing often arrests because persistent microbial biofilms perpetuate tissue destruction while matrix synthesis fails; in this setting, LL-37 provides the anti-biofilm clearance while GHK-Cu provides the regenerative building signal. LL-37 has demonstrated accelerated wound closure in Phase 2 clinical trials for venous leg ulcers, while topical GHK-Cu has proven efficacy in clinical trials for diabetic foot ulcers and facial photodamage.
Quick Comparison: LL-37 vs GHK-Cu
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | LL-37 | GHK-Cu |
|---|---|---|
| Primary wound phase | Acute / Inflammatory phase (Microbial clearance) | Proliferative & Remodeling phase (Matrix rebuilding) |
| Peptide structure | 37 amino acids: Amphipathic alpha-helix (4493.3 Da) | 3 amino acids: Gly-His-Lys:Cu2+ complex (403.9 Da) |
| Primary molecular target | Anionic bacterial cell membranes (Toroidal pore lysis) | Copper delivery, lysyl oxidase activation, collagen I/III synthesis |
| Antimicrobial potency | Broad-spectrum bactericidal (Pores disrupt bacteria in minutes) | Mild bacteriostatic synergy via copper; primary action is matrix repair |
| Extracellular matrix impact | Indirect (Clears infection allowing natural granulation) | Direct (Stimulates procollagen, elastin, and decorin transcription) |
| Human clinical trials | Phase 2 RCT in venous leg ulcer healing (Grönberg et al. 2014) | Multiple RCTs in diabetic foot ulcers and cosmetic dermatology |
| Mammalian cytotoxicity | Moderate (Hemolytic at high supraphysiological doses) | Negligible (Physiological endogenous copper complex) |
| WADA status | Not prohibited | Not prohibited |
Bactericidal Toroidal Pore Lysis vs Copper Fibrillogenesis
The contrast between physical microbial killing and biochemical tissue construction.
LL-37: Electrostatic Membrane Lysis & Anti-Biofilm Action
Primary Target: Bacterial anionic phospholipids; FPRL1/FPR2 receptor
Affinity Profile: High selectivity for bacterial phosphatidylglycerol over host cholesterol
LL-37's amphipathic alpha-helix binds electrostatically to bacterial cell walls. Upon reaching a critical surface concentration, peptide monomers insert into the outer leaflet, creating toroidal pores that dissipate membrane potential and leak metabolites, killing bacteria within minutes. LL-37 also degrades established bacterial biofilms and neutralizes pro-inflammatory endotoxins.
GHK-Cu: Collagen Fibrillogenesis & Tissue Remodeling
Primary Targets: Copper transport; integrin and proteoglycan interactions
Affinity Profile: Extremely high affinity for Cu(II) (log K = 16.4)
GHK-Cu delivers trace copper directly into the extracellular matrix, serving as an essential cofactor for lysyl oxidase, which cross-links tropocollagen into mature collagen fibrils. GHK-Cu upregulates decorin to ensure parallel fibril alignment and modulate TGF-beta-1, preventing excessive hypertrophic scarring while stimulating microvascular angiogenesis.
Phase 2 Clinical Development vs Cosmetic Formulation
The commercial and clinical standing of both peptides.
LL-37 Status & Formulations
Not approved by the FDA or EMA for human clinical use.
GHK-Cu Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Critical Regulatory Distinction
Neither peptide is an FDA-approved prescription drug product. LL-37 has been evaluated under exploratory clinical trial INDs; GHK-Cu is an established compliant ingredient in cosmetic skincare.
Venous Leg Ulcer Trials vs Diabetic Foot Ulcer Studies
Evaluating the human evidence base in chronic non-healing wounds.
LL-37: LL-37 Venous Leg Ulcer Trial (Grönberg et al., 2014)
In a 4-week randomized, double-blind Phase 2 trial in 34 patients with chronic non-healing venous leg ulcers, topical LL-37 demonstrated statistically significant dose-dependent acceleration of wound healing compared to placebo, with marked reduction in ulcer surface area.
GHK-Cu: GHK-Cu Diabetic Ulcer Clinical Evidence (Mulder et al., 1994)
In a multicenter randomized trial in patients with diabetic neuropathic ulcers, a 2% GHK-Cu topical gel increased the percentage of completely healed ulcers from 60.5% with conventional care to 98.5% with GHK-Cu, while significantly decreasing infection rates.
Comparative Tolerability & Application Safety
Both peptides are generally well tolerated in topical clinical applications.
| Safety Consideration | LL-37 | GHK-Cu |
|---|---|---|
| Topical skin tolerability | Well tolerated at therapeutic doses; excessive doses cause irritation | Exceptionally well tolerated; non-irritating in human patch testing |
| Systemic injection risks | Risk of mast cell degranulation and vascular permeability | Copper accumulation possible only with massive overdosing |
What LL-37 and GHK-Cu Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Endogenous Human Peptides
Both peptides are naturally synthesized biomolecules that play vital roles in human tissue preservation.
Wound Care Validation
Both have been evaluated in published human randomized clinical trials for accelerating non-healing dermal ulcers.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Biological Role
LL-37 is primarily a bactericidal pathogen killer; GHK-Cu is primarily an extracellular matrix builder.
Length & Structure
LL-37 is a 37-amino-acid amphipathic peptide; GHK-Cu is a tiny 3-amino-acid copper-chelated complex.
Membrane Effect
LL-37 forms pores that lyse cell membranes; GHK-Cu does not disrupt cellular membranes.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
LL-37 and GHK-Cu combined together make wounds heal in 24 hours
insufficientExaggerated online claim unsupported by wound healing physiology.
Wound healing requires a coordinated multi-week physiological sequence of hemostasis, inflammation, proliferation, and maturation. While both peptides accelerate cellular repair, normal tissue remodeling takes weeks to achieve tensile strength.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Antimicrobial Biofilm Clearance
LL-37 validated in microbial and clinical ulcer studies; GHK-Cu is not a primary antibiotic.
Human Dermal Collagen Synthesis
GHK-Cu validated across multiple human clinical and cosmetic trials; LL-37 lacks direct collagen data.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Dual-Action Regenerative Wound Dressings
Engineering hydrogel wound dressings that release LL-37 during the first 48 hours for sterilization, followed by sustained GHK-Cu release for granulation and epithelialization.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Peer-Reviewed RCT
Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers
-
Peer-Reviewed RCT
Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper